Surface Oncology to Present at the Baird Global Healthcare Conference
Surface Oncology (Nasdaq: SURF) announced a presentation at the Robert W. Baird Global Healthcare Conference on September 10, 2020. CEO Jeff Goater and CMO Robert Ross will discuss their lead immunotherapy programs, SRF617, targeting CD39, and SRF388, targeting IL-27, along with the preclinical pipeline, including SRF813, which targets CD112R (PVRIG).
The fireside chat is set for 1:25 pm EDT and will highlight Surface's innovative approach to cancer treatment via next-generation immunotherapies aimed at the tumor microenvironment.
- None.
- None.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will present at the upcoming Robert W. Baird Global Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).
The presentation will be in the format of a fireside chat and take place virtually on Thursday September 10, 2020 at 1:25 pm EDT.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698
Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397
FAQ
What is the date of the Surface Oncology presentation at the Baird Global Healthcare Conference?
Who will present at the Robert W. Baird Global Healthcare Conference for SURF?
What programs will Surface Oncology discuss at the conference?
What is the focus of Surface Oncology's pipeline?
What time is the Surface Oncology presentation at the Global Healthcare Conference?
